Lev Gerlovin and Walter Colasante discuss the challenges posed to the biopharma business model by revolutionary, but prohibitively expensive, cell and gene therapies. To improve efficiencies and mitigate risk, drug developers now are looking at new options in stakeholder engagement and collaboration, as well as identifying new options for financing.
Read more here in The Pharma Letter Expert View: https://www.thepharmaletter.com/article/building-new-business-models-to-…
The authors wish to acknowledge the contributions of Pascale Diesel, Stephanie Donahue, and Michael Krepps to this article.
Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant...